Hospital Clínico Universitario de Valencia

Schizophrenia has a heritability of 60–80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies. A genome-wide association study including over 76,000 individuals with schizophrenia and over 243,000 control individuals identifies common variant associations at 287 genomic loci, and further fine-mapping analyses highlight the importance of genes involved in synaptic processes.

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

BACKGROUND: Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment. METHODS: From April 2005 through November 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations. The analysis was performed in a central laboratory. Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment. RESULTS: EGFR mutations were found in 350 of 2105 patients (16.6%). Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P<0.001 for all comparisons). The mutations were deletions in exon 19 (62.2%) and L858R (37.8%). Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 months and 27 months, respectively. The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P<0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P=0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P=0.02). The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%). CONCLUSIONS: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.

BACKGROUND: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survival. RESULTS: A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at high risk for progression, and 70% had stage IIIC or IV ovarian cancer. Progression-free survival (restricted mean) at 36 months was 20.3 months with standard therapy, as compared with 21.8 months with standard therapy plus bevacizumab (hazard ratio for progression or death with bevacizumab added, 0.81; 95% confidence interval, 0.70 to 0.94; P=0.004 by the log-rank test). Nonproportional hazards were detected (i.e., the treatment effect was not consistent over time on the hazard function scale) (P<0.001), with a maximum effect at 12 months, coinciding with the end of planned bevacizumab treatment and diminishing by 24 months. Bevacizumab was associated with more toxic effects (most often hypertension of grade 2 or higher) (18%, vs. 2% with chemotherapy alone). In the updated analyses, progression-free survival (restricted mean) at 42 months was 22.4 months without bevacizumab versus 24.1 months with bevacizumab (P=0.04 by log-rank test); in patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months with standard therapy alone and 18.1 months with bevacizumab added, with respective median overall survival of 28.8 and 36.6 months. CONCLUSIONS: Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Committee; LVH: left ventricular hypertrophy; LVM: left ventricular mass; PDE-5: phosphodiesterase-5; PPAR-γ: peroxisome proliferators-activated receptor-γ; PWV: pulse wave velocity; SBP: systolic blood pressure; WHO: World Health Organization. Introduction In the 2 years since the publication of the 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) [1], research on hypertension has actively been pursued and the results of new important studies (including several large randomized trials of antihypertensive therapy) have been published. Some of these studies have reinforced the evidence on which the recommendations of the 2007 ESH/ESC guidelines were based. However, other studies have widened the information available in 2007, modifying some of the previous concepts, and suggesting that new evidence-based recommendations could be appropriate. The aim of this document of the ESH is to address a number of studies on hypertension published in the last 2 years in order to assess their contribution to our expanding knowledge of hypertension. Furthermore, some critical appraisal of the current recommendations of the ESH/ESC, as well as of other guidelines, might be a useful step toward the preparation of a third version of the European guidelines in the future. The most important conclusions are summarized in boxes. The points that will be discussed are reported in Box 1.Box. 1Assessment of subclinical organ damage for stratification of total cardiovascular risk The 2007 ESH/ESC guidelines recommend total cardiovascular risk be evaluated in each patient to decide about important aspects of treatment: the blood pressure (BP) threshold at which to commence drug administration, the target BP to be reached by treatment, the use of two-drug combinations as the initial treatment step, and the possible addition to the antihypertensive treatment regimen of lipid-lowering and antiplatelet agents [1]. Among the criteria to assess total cardiovascular risk, the European guidelines consider subclinical organ damage to be a very important component, because asymptomatic alterations of the cardiovascular system and the kidney are crucial intermediate stages in the disease continuum that links risk factors such as hypertension to cardiovascular events and death. On the basis of a number of criteria (prognostic importance, prevalence in the population, availability and cost of the assessment procedures, etc.), the 2007 European guidelines considered detection of organ damage as important for the diagnostic and prognostic evaluation of hypertensive patients. They further subdivided the different types of organ damage into (1) those that can be identified by relatively simple and cheap procedures [electrocardiogram, serum creatinine, estimated glomerular filtration rate (eGFR), and measurement of urinary protein excretion in order to detect microalbuminuria or proteinuria], which were thus regarded as suitable for routine search in the whole hypertensive population, and (2) those that require more complex procedures or instrumentations (echocardiogram, carotid ultrasonography, pulse wave velocity), which were for this reason only recommended for a more in-depth characterization of the hypertensive patient. Since then, other studies have added useful information on the importance of detecting subclinical organ damage in the hypertensive population, strengthening the recommendation to use the most easily available and the least costly procedures in the routine examination of individuals with hypertension. Heart A few recent papers have revived interest in the of the to the risk of cardiovascular In a a new of left ventricular the of left ventricular that is on and has been reported to be to cardiovascular The for and Furthermore, in the the have reported that in hypertensive with left individuals at risk of cardiovascular cardiovascular and for a very recent on the in as with left ventricular and of cardiovascular events hypertension is by risk for each evidence is available on the of as by of interest because of to more and and A has information more and hypertensive with left ventricular left ventricular left ventricular in of the left ventricular and and the risk of as large as that of with left ventricular in on population, the left ventricular and for and only in the risk with has been by other In a on a of hypertensive for with a of and cardiovascular events and with for cardiovascular risk factors Furthermore, a of hypertensive in the that cardiovascular events about more in with a or more with those with a this in the population, with a to in cardiovascular and were for a large number of and BP A in the risk more risk the The of carotid and with cardiovascular discussed in the 2007 guidelines, has been further by which have that carotid cardiovascular events of BP and and this for the at the carotid and for the at the of the carotid that by the at the and by the carotid prognostic in addition to that of prognostic of carotid has been reported in a of of the of cardiovascular which for about years has on the prognostic of arterial In the population, pulse wave with a in the risk of a cardiovascular Furthermore, of for cardiovascular events has been in for years of and wave such as BP and have been as of cardiovascular events in recent studies In in of these studies of and hypertensive only and cardiovascular for cardiovascular risk and carotid However, be that in most available the of BP pressure which the BP be considered in the of hypertensive in of further new the evidence on the prognostic of that available at the of the 2007 guidelines [1]. In the of in the with a of cardiovascular events and in the and with a in the of and cardiovascular events for cardiovascular risk and of in a of the to the of and to the different and more of the to the which only of The by the to be of and cardiovascular events in the large number of 2 in the were for the urinary protein excretion of the risk of cardiovascular events the in the risk of cardiovascular and events and evidence is available to the large of in of the prognostic of the in urinary protein as microalbuminuria In the and the microalbuminuria as important of cardiovascular the and in with microalbuminuria with those In the the of microalbuminuria with a In the a of to the with a and in the risk of cardiovascular cardiovascular and this the the to microalbuminuria The of urinary protein excretion and were of each other and the of microalbuminuria and about in for cardiovascular for cardiovascular and for of organ damage The 2007 European guidelines a number of of organ damage for which evidence of prognostic use in the could be because of of such as the cost and availability of the the and in the procedures, and in several the of of the and on the evidence available in the last 2 addition to the of organ damage in the 2007 guidelines can be the availability of more and the cost of their use about by In this the use of in a very recent in a of hypertensive cardiovascular disease has the information that are more and subclinical and in the of other of organ damage evidence these to a of importance because of the of the more and more in diagnostic procedures, disease is to more in prognostic and studies in hypertension. The prognostic of alterations in has been by studies However, the of this measurement of this A new for the of for evaluation to be on a of a that has been actively in the In a of individuals cardiovascular disease with hypertension and with the of the of cardiovascular this of cardiovascular risk factors in the large of of the Health added very to the prognostic of risk factors On the have reported that in a of hypertensive for about of the the with a in cardiovascular events for cardiovascular risk However, the of have reported that in the of hypertensive of cardiovascular events because in different have a different prognostic the prognostic of in hypertension to be further be that the addition of new of organ damage to the assessment of total cardiovascular risk only the of their prognostic importance, has to the to the of cardiovascular is by to be and are available that in some new risk factors of prognostic added to the the by which cardiovascular risk can be thus only the diagnostic procedures more and is by the recent results of the which that of to in the and by which total cardiovascular risk organ damage as a of cardiovascular risk subclinical organ damage the of cardiovascular risk, the the patient into the that risk of at least cardiovascular events in years patients. The 2007 European guidelines hypertensive with subclinical organ damage those with a total cardiovascular is further by more recent evidence on the contribution of subclinical and damage to the total cardiovascular to subclinical of the by some of the studies that in hypertensive of the is with of cardiovascular events to or in years in years has been reported for for with in the in the hypertensive of the with a of cardiovascular events of with the in evidence for In the of the Health the of cardiovascular events the carotid or more and and in those with in the In the hypertensive of the the of and cardiovascular events in years carotid in the third and or at least been In with in the or the cardiovascular events in In hypertensive the of cardiovascular events or more and in those with in the and Furthermore, asymptomatic disease as by a has been to be in with of cardiovascular events in years and recent evidence that in hypertensive subclinical organ damage is with a risk of cardiovascular events of or has been reported some years that by a serum more is with a of cardiovascular events or more In the recent of hypertensive a with cardiovascular events of about in with Furthermore, in the hypertensive by the of disease in years in the of microalbuminuria and of only in in the the of cardiovascular events in only in those individuals in microalbuminuria in the with in the of these hypertension. The 2007 European guidelines with subclinical organ damage as at risk BP is in the evidence that this is the is In the of the information available on the prognostic of in the and hypertensive Furthermore, in the population, the of with cardiovascular events for cardiovascular risk BP In the microalbuminuria with only a cardiovascular in that a risk to the and in the individuals of the a microalbuminuria the with a rate of cardiovascular events of only in years with a rate in individuals with microalbuminuria the of of subclinical organ damage The 2007 European guidelines have that of organ damage the of cardiovascular that organ damage be to the in the in which hypertensive in treatment by of or a in cardiovascular those in or to that in and in other studies a in and or cardiovascular with in treatment or in with a of cardiovascular events and to Since 2007, on the in damage and cardiovascular have been by further of the which have that in left left ventricular and in of with cardiovascular rate Furthermore, have been that in in treatment cardiovascular the of in the carotid has for the been in a recent of to a of the of these with the large in to conclusions The of in with cardiovascular has been by some of the In this on a large number of or very cardiovascular risk the with a of angiotensin-converting and the in the on with or the other this by a in cardiovascular events and with in events However, these results the important that in can be a of the more or of treatment because for the results are in most a and few which in a very number of the that for that Furthermore, in the very cardiovascular risk the of the system by the and might have of that and the with a in In of this are some recent of the in with 2 In these of a with and cardiovascular the contribution of to the of on the important prognostic of subclinical organ damage to In hypertensive and the population, the of and a carotid or arterial a by the or microalbuminuria or the total cardiovascular risk, hypertensive into the risk The in or by treatment the on cardiovascular information on are more or by the treatment some recent results evidence that this is the for in urinary protein the for the of subclinical organ damage is of crucial importance in the hypertensive assessment can use of simple and cheap procedures that can routine information and at can on more that can further and In organ damage assessment is useful because of the evidence that in the of of organ damage to the cardiovascular risk be more with to the cardiovascular risk is published subclinical organ damage can total cardiovascular risk to the in with However, organ damage is or or is by risk is with a or in risk in individuals and the 2007 guidelines recommend risk as a for the of treatment in and patients. In this is important to that the of organ damage in that decide to the of several studies that the of cardiovascular events is in in hypertensive for cardiovascular risk factors and is with the that antihypertensive treatment a total risk to a the that in treatment is organ damage is use of organ damage assessment thus to a more about the of treatment and thus Some of the discussed in of subclinical organ damage for stratification of total cardiovascular risk are summarized in Box guidelines on the management of hypertension recommend the of antihypertensive in with a or more a or and to the treatment in order for the to be these They further recommend drug treatment to be a BP that a and and a and in with or a of cardiovascular or at The 2007 ESH/ESC guidelines have these recommendations with information on the evidence are and a critical of this has been by of the in the of further information by recent The of the ESH document is to the and the of evidence on which these recommendations are and thus the and of studies which possible evidence to antihypertensive treatment recommend use of antihypertensive in with hypertension at or cardiovascular risk, that BP is and and treatment has However, be that the evidence in of this recommendation is because trials of on BP could be those hypertension or the recent which in the 2007 guidelines to in with cardiovascular risk, evidence because BP a large of antihypertensive at and a number of evidence of organ damage or a of cardiovascular to the or that the BP threshold for drug treatment is to and recommend antihypertensive at at least or at least in the as However, as in is on hypertensive that with a in the hypertension can be that current guidelines recommendations on BP at which to drug treatment in the are on results other and by the large of antihypertensive in available trials in the at initial blood and at in antihypertensive treatment trials in the is for the guidelines recommendation to drug treatment in the BP have are on the results of the of the which has important as a the the the in and a of cardiovascular events in the randomized to more treatment to the of to other cardiovascular of large and However, in by BP were and the of cardiovascular in the in the of antihypertensive treatment in with or in those in this were stratification on the or of a of hypertension. have been recommendations to antihypertensive treatment at BP in with previous have been on the the that in with a previous or BP by a in the of and cardiovascular events in hypertensive and patients. However, in this hypertension by of or and in a a in with treatment only or more Furthermore, BP in were reported of treatment in of the and be to on of treatment in patients. the of evidence of has been by the results of a more recent large of antihypertensive treatment in with the these results be to a more in a more discussed in the 2007 European guidelines and further in a recent trials are available the information drug treatment be at BP in with disease is in most to the of the to the which were in these were subdivided for their or BP on a of antihypertensive drug administration, and thus the to a BP the results and trials pressure The evidence available on the BP of antihypertensive treatment has been by some of this and is summarized in in the in of trials in hypertensive to in the actively at or this in the or In of the BP with a in and in this for that were and the in a previous were at or cardiovascular risk and with this evidence the recommendation of guidelines to to in the of with or 2 hypertension and or total cardiovascular this recommendation to hypertensive is by in the of in trials the of hypertensive randomized to more treatment a of cardiovascular in the only with results the were to is evidence in of the guidelines recommendation to the target in patients. The of that the guidelines recommendation to BP in with or a of cardiovascular disease is by the recommendation in of treatment to the by some such as and a of cardiovascular for a BP in in hypertensive patients. in the of only in were and were with a in cardiovascular results trials in with a of or disease with the that in some trials in which to with the with of of trials and trials on organ damage on BP and for drug treatment has been of trials and studies on the of treatment on organ damage of prognostic importance, this is of the of cardiovascular events in to the BP by treatment have been in the large of hypertensive of the in the cardiovascular risk for the the and the and in the with of the In the the of cardiovascular events at a of and a of In the hypertensive in the BP a in the of cardiovascular events and with to the in BP these of the of treatment In the the of cardiovascular events as the of in which BP to be were for and The cardiovascular with a for cardiovascular events to as the to about On the in the of BP were initial were for were and at each initial a BP by a cardiovascular However, in in initial in the the and for have been reported for the of in in the with of the of to to cardiovascular and to of as well as in disease to the BP and subclinical organ the have that the of is to the BP by treatment, the for large BP the A published has that of is by as with BP and in hypertensive Furthermore, several studies have evidence that antihypertensive treatment is by a or a in urinary protein be in the or initial BP is The most recent evidence has been by the which has that in most of antihypertensive treatment, further BP by the addition of and the of of the the or the of urinary protein a of initial systolic or diastolic BP to The for a and in the actively as with the at initial or and Furthermore, this of the has the risk of a to as the treatment to of about The has been some a for of on the of some trials as well as of the results of other trials on have the that in at cardiovascular risk, antihypertensive treatment that to or and be by a further in the of that by a has to the as to BP is and in of cardiovascular The is to the a BP which organ is studies in of cardiovascular disease that the BP and cardiovascular rate is to very BP which are only by antihypertensive is possible that in cardiovascular risk of the that blood the BP threshold which organ is However, the of this be different in to the of organ damage and has been by trials to the of more BP for initial and of results the that in the in which BP could have been a initial cardiovascular risk that the BP and the of cardiovascular this is by the evidence of a in of several trials these the of cardiovascular by a of BP that is and and suggesting that this BP the in cardiovascular are is in with the results of studies that the BP and cardiovascular events is cardiovascular events are on a which at BP the 2007 recommendations the evidence is to in hypertensive at and risk, drug be BP to or a suitable with with the to BP this of antihypertensive treatment in hypertension for BP to to 2 or organ damage to is by a recent of trials with antihypertensive agents has that in trials on cardiovascular risk the that the risk by lipid-lowering and antiplatelet can very the a cardiovascular events in by a initial risk On the in trials hypertensive at initial or risk, the could be to in which that of antihypertensive be threshold and target for drug treatment in the the current availability of well BP to be with in or in cardiovascular or of antihypertensive drug in with BP is by is the for the BP recommended for in large and are more in the subclinical organ and microalbuminuria and to be the to decide the BP for treatment as well as treatment in patients. and at least the of studies such as which the of BP or are be useful to recommend that in be well that are be in with the results of the in which the and of antihypertensive treatment were in in to with on in at recommendations can be to with previous cardiovascular for current evidence is of antihypertensive drug treatment BP is in the and the of at a BP target of has been in those with a BP that the 2007 ESH/ESC guidelines as at cardiovascular risk because of the of risk or subclinical organ has been that this BP subclinical organ damage to a cardiovascular risk, and is this The evidence in of in these is to that reported by the and the studies in which of antihypertensive drug the of hypertension the of the this be pursued with or with addition of antihypertensive agents last recommendations for a number of of patient management randomized trials can only for a few years and of the results to the of is The to into that the of antihypertensive treatment more with because of organ damage has a in with the of large and with a BP to be by the results of the few trials in which were for a number of years of randomized In the and for the of antihypertensive treatment on the of cardiovascular events years of the of the the that antihypertensive treatment in the A which is to as the has been reported for the 2 which reported a on the and of 2 years of with that antihypertensive and in the a of the of a previous blood in The most important points to threshold and target BP for treatment are summarized in and of antihypertensive In their and 2007 [1], the European guidelines the large number of randomized trials of antihypertensive those treatment and those treatment on different They that the of antihypertensive treatment are to of BP and are of the well as and and can BP and and cardiovascular these are suitable for the and of antihypertensive treatment as or in some combinations with each of the of the of antihypertensive and of agents a has been a in the by the of a by in and in the with the as for and the of by their has been by different of on a possible of and as well as on the possible of for and of for disease to possible or of new and is of and and be by of guidelines On the be to of the of The evidence which have been as antihypertensive and in the recommendations discussed in the 2007 European on the of in antihypertensive have been added since In a of of randomized trials of a has been reported the rate by and cardiovascular the the the the of and to be by On the a recent of randomized trials only a of in with other a as other agents on events and and a other in with a recent Furthermore, the recent publication of a of the and in has the of cardiovascular to be in on the or the with a in the is with of large of on different antihypertensive treatment for in randomized that the of cardiovascular on treatment on other antihypertensive agents has been of the possible of a BP by treatment in those trials in which to have a on of on in the of the that the very to the because of the in and On the to be to other antihypertensive agents in their to A recent more hypertensive different has a of in However, studies for the be with with other antihypertensive agents because of a wave to to be on antihypertensive management be because the and is to at hypertension and antihypertensive treatment are most is that as well as have and in such as those with the or The importance of this have been by the results of most studies and trials have been that by of in or in to of or with a blood a recent of the has that new of at the of this in at are by a number of in which of at at the of the However, the for Furthermore, is the as with some studies that with have a of cardiovascular the and several years the conclusions in other studies is with other agents in trials subclinical organ damage as have been to be and in left ventricular carotid and and this be to in cardiovascular in the be that are a and that such as and to some of the for other and pulse pressure at the BP rate and because of the with has on BP In the on total and and at has been to and to have the as and have been in trials in in and of the of and in treatment by and in the the on or with in of microalbuminuria and to in hypertensive and has been to and left ventricular pressure in the hypertensive the cardiovascular by and in with is in hypertension to be in a A for in antihypertensive such as that to these in the is of The evidence that a BP by can types of cardiovascular events is be that most of the the of which has been the basis for on have to the of these drug the of and is to and has been have been in for their to organ and have been to or Furthermore, large studies that have the of of antihypertensive agents on to have to with the least or those by the least on treatment a recent has reported for for In the results of the be discussed in the drug combinations have as to are the of and The that be to other antihypertensive agents in has been on the basis of some and A to the that be to in has been On the has been that be to in these concepts, as well as their have been by the results of the very large cardiovascular treatment with or has to be to as as the of a are A of on and more recent trials the that and have the on The by the relatively BP by treatment is more to because in and for could a is to decide the has to be with the of the several years or with the of the on to The of with a of cardiovascular events in because prevalence of in to that in or because of a of and have some information on the of and on the of new in patients. the that has been to of new different and in and only and were in and in with to the However, most were other antihypertensive agents that have the of the these the that a have been the of a of events by the the On the some recent that these agents have some in is this can be to a or to a BP in the patients. is are in as is in several studies and large The recent by that trials in which a BP antihypertensive and the

BACKGROUND: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. METHODS: We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. RESULTS: Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). CONCLUSIONS: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.

AIMS/HYPOTHESIS: The Di@bet.es Study is the first national study in Spain to examine the prevalence of diabetes and impaired glucose regulation. METHODS: A population-based, cross-sectional, cluster sampling study was carried out, with target population being the entire Spanish population. Five thousand and seventy-two participants in 100 clusters (health centres or the equivalent in each region) were randomly selected with a probability proportional to population size. Participation rate was 55.8%. Study variables were a clinical and demographic structured survey, lifestyle survey, physical examination (weight, height, BMI, waist and hip circumference, blood pressure) and OGTT (75 g). RESULTS: Almost 30% of the study population had some carbohydrate disturbance. The overall prevalence of diabetes mellitus adjusted for age and sex was 13.8% (95% CI 12.8, 14.7%), of which about half had unknown diabetes: 6.0% (95% CI 5.4, 6.7%). The age- and sex-adjusted prevalence rates of isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT) and combined IFG-IGT were 3.4% (95% CI 2.9, 4.0%), 9.2% (95% CI 8.2, 10.2%) and 2.2% (95% CI 1.7, 2.7%), respectively. The prevalence of diabetes and impaired glucose regulation increased significantly with age (p < 0.0001), and was higher in men than in women (p < 0.001). CONCLUSIONS/INTERPRETATION: The Di@bet.es Study shows, for the first time, the prevalence rates of diabetes and impaired glucose regulation in a representative sample of the Spanish population.

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.

The aim of the present study was to assess reproducibility and relative validity of a self-administered FFQ used in the PREDIMED Study, a clinical trial for primary prevention of CVD by Mediterranean diet in a population at high cardiovascular risk. The FFQ was administered twice (FFQ1 and FFQ2) to explore reproducibility at 1 year. Four 3 d dietary records (DR) were used as reference to explore validity; participants therefore recorded their food intake over 12 d in the course of 1 year. The degree of misclassification in the FFQ was also evaluated by a contingency table of quintiles comparing the information from the FFQ2 and the DR. A total of 158 men and women (aged 55-80 years) were asked not to modify their dietary habits during the study period. Reproducibility for food groups, energy and nutrient intake, explored by the Pearson correlation coefficient (r) ranged 0.50-0.82, and the intraclass correlation coefficient (ICC) ranged from 0.63 to 0.90. The FFQ2 tended to report higher energy and nutrient intake than the DR. The validity indices of the FFQ in relation to the DR for food groups and energy and nutrient intake ranged (r) from 0.24 to 0.72, while the range of the ICC was between 0.40 and 0.84. With regard to food groups, 68-83 % of individuals were in the same or adjacent quintile in both methods, a figure which decreased to 55-75 % for energy and nutrient intake. We concluded that FFQ measurements had good reproducibility and a relative validity similar to those of FFQ used in other prospective studies.

Many important decisions on hypertension management must currently be taken without the support of evidence&#13;\nfrom large randomized controlled trials. The following issues appear in urgent need to be approached by simply&#13;\ndesigned trials.&#13;\n(1) Should antihypertensive drugs be prescribed to all patients with grade 1 hypertension, even when total&#13;\ncardiovascular risk is relatively low or moderate? Because of the very low rate of cardiovascular events&#13;\nexpected in these patients, a placebo-controlled trial using intermediate endpoints such as signs of organ&#13;\ndamage of recognized prognostic importance would be feasible, ethical, and clinically relevant.&#13;\n(2) Should antihypertensive drugs be prescribed to the elderly with grade 1 hypertension, and should antihypertensive&#13;\ntreatment achieve a goal of below 140/90mmHg also in the elderly? These trials could make use&#13;\nof hard cardiovascular outcomes and could be placebo-controlled.&#13;\n(3) Should antihypertensive drug treatment be started in diabetic patients or in patients with previous cerebrovascular&#13;\nor cardiovascular disease when BP is still in the high normal level, and should BP goal be below 130/&#13;\n80mmHg in these patients? These issues can be approached by placebo-controlled trials because no trial&#13;\nevidence is still available on the benefit of lowering high normal BP or of achieving BP goals below 130/&#13;\n80mmHg.&#13;\n(4) What are the lowest safe BP values to achieve by treatment in different clinical conditions? This issue should&#13;\nbe approached by trials comparing more or less intense BP-lowering treatment strategies in patients with&#13;\ndifferent cardiovascular risk levels.&#13;\n(5) Are lifestyle measures known to reduce BP also capable of reducing morbidity and mortality in hypertension?&#13;\nA controlled randomized trial using intermediate endpoints (organ damage) would be feasible and desirable&#13;\nin patients with high normal BP or grade 1 hypertension.

This document summarizes the available evidence and provides recommendations on the use of home blood pressure monitoring in clinical practice and in research. It updates the previous recommendations on the same topic issued in year 2000. The main topics addressed include the methodology of home blood pressure monitoring, its diagnostic and therapeutic thresholds, its clinical applications in hypertension, with specific reference to special populations, and its applications in research. The final section deals with the problems related to the implementation of these recommendations in clinical practice.

Hypertension in children and adolescents has gained ground in cardiovascular medicine, thanks to the progress made in several areas of pathophysiological and clinical research. These guidelines represent a consensus among specialists involved in the detection and control of high blood pressure in children and adolescents. The guidelines synthesize a considerable amount of scientific data and clinical experience and represent best clinical wisdom upon which physicians, nurses and families should base their decisions. They call attention to the burden of hypertension in children and adolescents, and its contribution to the current epidemic of cardiovascular disease, these guidelines should encourage public policy makers, to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents.

BACKGROUND AND PURPOSE: Headache disorders are very common, but their monetary costs in Europe are unknown. We performed the first comprehensive estimation of how economic resources are lost to headache in Europe. METHODS: From November 2008 to August 2009, a cross-sectional survey was conducted in eight countries representing 55% of the adult EU population. Participation rates varied between 11% and 59%. In total, 8412 questionnaires contributed to this analysis. Using bottom-up methodology, we estimated direct (medications, outpatient health care, hospitalization and investigations) and indirect (work absenteeism and reduced productivity at work) annual per-person costs. Prevalence data, simultaneously collected and, for migraine, also derived from a systematic review, were used to impute national costs. RESULTS: Mean per-person annual costs were €1222 for migraine (95% CI 1055-1389; indirect costs 93%), €303 for tension-type headache (TTH, 95% CI 230-376; indirect costs 92%), €3561 for medication-overuse headache (MOH, 95% CI 2487-4635; indirect costs 92%), and €253 for other headaches (95% CI 99-407; indirect costs 82%). In the EU, the total annual cost of headache amongst adults aged 18-65 years was calculated, according to our prevalence estimates, at €173 billion, apportioned to migraine (€111 billion; 64%), TTH (€21 billion; 12%), MOH (€37 billion; 21%) and other headaches (€3 billion; 2%). Using the 15% systematic review prevalence of migraine, calculated costs were somewhat lower (migraine €50 billion, all headache €112 billion annually). CONCLUSIONS: Headache disorders are prominent health-related drivers of immense economic losses for the EU. This has immediate implications for healthcare policy. Health care for headache can be both improved and cost saving.

BACKGROUND: Patients with type 1 diabetes mellitus and microalbuminuria often have elevated blood pressure while they are asleep, but it is not known whether the elevation develops concomitantly with microalbuminuria or precedes it. METHODS: We monitored 75 adolescents and young adults who had had type 1 diabetes with normal urinary albumin excretion and blood pressure for more than five years. Ambulatory blood-pressure monitoring was used to assess blood pressure at the initial evaluation and about two years later, at which time all subjects had normal urinary albumin excretion. Subsequently, subjects were monitored for the development of microalbuminuria. RESULTS: Microalbuminuria developed in 14 subjects, whereas the other 61 continued to have normal urinary albumin excretion. The mean (+/-SD) systolic pressure during sleep increased significantly in the subjects who ultimately had microalbuminuria (from 109.9+/-11.3 to 114.9+/-11.7 mm Hg, P=0.01) but not in the subjects with normal albumin excretion (from 106.0+/-8.8 to 106.4+/-14.8 mm Hg). The risk of progression to microalbuminuria was examined in relation to the ratio of systolic pressure during sleep to systolic pressure in the daytime. A ratio of 0.9 or lower, used to define a normal fall in nocturnal pressure, had a negative predictive value of 91 percent for the development of microalbuminuria. Moreover, the risk of microalbuminuria was 70 percent lower (95 percent confidence interval, 44 to 110 percent) in subjects with a ratio of 0.9 or less than in those with a ratio higher than 0.9 (P=0.01). CONCLUSIONS: In persons with type 1 diabetes, an increase in systolic blood pressure during sleep precedes the development of microalbuminuria. In those whose blood pressure during sleep decreases normally, the progression from normal albumin excretion to microalbuminuria appears to be less likely.

These practice guidelines on the management of arterial hypertension are a concise summary of the more extensive ones prepared by the Task Force jointly appointed by the European Society of Hypertension and the European Society of Cardiology. These guidelines have been prepared on the basis of the best available evidence on all issues deserving recommendations; their role must be educational and not prescriptive or coercive for the management of individual subjects who may differ widely in their personal, medical and cultural characteristics. The members of the Task Force have participated independently in the preparation of these guidelines, drawing on their academic and clinical experience and by objective examination and interpretation of all available literature. A disclosure of their potential conflict of interest is reported on the websites of the ESH and the ESC.

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.

This retrospective longitudinal study was undertaken in order to determine the incidence and reproductive impact of uterine malformations on women desiring to conceive during their reproductive years. A total of 3181 patients in whom the morphology of the uterus was ascertained by hysterosalpingography (HSG) and laparoscopy/laparotomy during the years 1980-1995 was included in the study. The population analysed included fertile, infertile and sterile patients. The overall frequency of uterine malformations was 4.0%. Infertile patients (6.3%) had a significantly (P < 0.05) higher incidence of Müllerian anomalies, in comparison with fertile (3.8%) and sterile (2.4%) women. Septate (33.6%) and arcuate (32.8%) uteri were the most common malformations observed. Each malformation was individually analysed in fertile and infertile patients, in order to ascertain its actual reproductive impact. The performance of the unicornuate and didelphys uteri was similar with a chance of having a living child of 37-40%. The reproductive potential of the bicornuate uterus showed a live birth rate of 62.5% and the septate uterus showed a live birth rate of 62%. In all these abnormalities, early miscarriages (25-38%) and preterm deliveries (25-47%) were quite common. The arcuate uterus presented a live birth rate of 82.7%. It is concluded that uterine anomalies are relatively frequent in fertile women, and more frequent in infertile patients. Nevertheless, fertile patients with normal reproductive performance do exist, and Müllerian defects can permit an absolutely normal obstetric outcome. The reproductive performance of the unicornuate and didelphys uteri was poor, while that of the septate and bicornuate uteri was better than expected. The arcuate uterus had no impact on reproduction.

IMPORTANCE: There are inconsistencies in concept, criteria, practice, and documentation of brain death/death by neurologic criteria (BD/DNC) both internationally and within countries. OBJECTIVE: To formulate a consensus statement of recommendations on determination of BD/DNC based on review of the literature and expert opinion of a large multidisciplinary, international panel. PROCESS: Relevant international professional societies were recruited to develop recommendations regarding determination of BD/DNC. Literature searches of the Cochrane, Embase, and MEDLINE databases included January 1, 1992, through April 2020 identified pertinent articles for review. Because of the lack of high-quality data from randomized clinical trials or large observational studies, recommendations were formulated based on consensus of contributors and medical societies that represented relevant disciplines, including critical care, neurology, and neurosurgery. EVIDENCE SYNTHESIS: Based on review of the literature and consensus from a large multidisciplinary, international panel, minimum clinical criteria needed to determine BD/DNC in various circumstances were developed. RECOMMENDATIONS: Prior to evaluating a patient for BD/DNC, the patient should have an established neurologic diagnosis that can lead to the complete and irreversible loss of all brain function, and conditions that may confound the clinical examination and diseases that may mimic BD/DNC should be excluded. Determination of BD/DNC can be done with a clinical examination that demonstrates coma, brainstem areflexia, and apnea. This is seen when (1) there is no evidence of arousal or awareness to maximal external stimulation, including noxious visual, auditory, and tactile stimulation; (2) pupils are fixed in a midsize or dilated position and are nonreactive to light; (3) corneal, oculocephalic, and oculovestibular reflexes are absent; (4) there is no facial movement to noxious stimulation; (5) the gag reflex is absent to bilateral posterior pharyngeal stimulation; (6) the cough reflex is absent to deep tracheal suctioning; (7) there is no brain-mediated motor response to noxious stimulation of the limbs; and (8) spontaneous respirations are not observed when apnea test targets reach pH <7.30 and Paco2 ≥60 mm Hg. If the clinical examination cannot be completed, ancillary testing may be considered with blood flow studies or electrophysiologic testing. Special consideration is needed for children, for persons receiving extracorporeal membrane oxygenation, and for those receiving therapeutic hypothermia, as well as for factors such as religious, societal, and cultural perspectives; legal requirements; and resource availability. CONCLUSIONS AND RELEVANCE: This report provides recommendations for the minimum clinical standards for determination of brain death/death by neurologic criteria in adults and children with clear guidance for various clinical circumstances. The recommendations have widespread international society endorsement and can serve to guide professional societies and countries in the revision or development of protocols and procedures for determination of brain death/death by neurologic criteria, leading to greater consistency within and between countries.

BACKGROUND: Reverse-transcriptase inhibitors have only moderate clinical efficacy against the human immunodeficiency virus type 1 (HIV-1). Ritonavir is an inhibitor of HIV-1 protease with potent in vitro anti-HIV properties and good oral bioavailability. METHODS: We evaluated the antiviral activity and safety of ritonavir in a double-blind, randomized, placebo-controlled phase 1 and 2 study of 84 HIV-positive patients with 50 or more CD4+ lymphocytes per cubic millimeter. The patients were randomly assigned to one of four regimens of ritonavir therapy, or to placebo for four weeks and then (by random assignment) to one of the ritonavir regimens. RESULTS: During the first 4 weeks, increases in CD4+ lymphocyte counts and reductions in the log number of copies of HIV-1 RNA per milliliter of plasma were similar among the four dosage groups, but in the three lower-dosage groups there was a return to base-line levels by 16 weeks. After 32 weeks, in the seven patients in the highest-dosage group (600 mg of ritonavir every 12 hours), the median increase from base line in the CD4+ lymphocyte count was 230 cells per cubic millimeter, and the mean decrease in the plasma concentration of HIV-1 RNA (as measured by a branched-DNA assay) was 0.81 log (95 percent confidence interval, 0.40 to 1.22). In a subgroup of 17 patients in the two higher-dosage groups, RNA was also measured with an assay based on the polymerase chain reaction, and after eight weeks of treatment there was a mean maximal decrease in viral RNA of 1.94 log (95 percent confidence interval, 1.37 to 2.51). Adverse events included nausea, circumoral paresthesia, elevated hepatic aminotransferase levels, and elevated triglyceride levels. Ten withdrawals from the study were judged to be related to ritonavir treatment. CONCLUSIONS: In this short-term study, ritonavir was well tolerated and had potent activity against HIV-1, but its clinical benefits remain to be established.

BACKGROUND: Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. METHODS: We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of a conditioning regimen. A total of 168 patients were enrolled at 27 centers. Patients were randomly assigned in a 1:1 ratio to receive ATG or not receive ATG, with stratification according to center and risk of disease. RESULTS: After a median follow-up of 24 months, the cumulative incidence of chronic GVHD was 32.2% (95% confidence interval [CI], 22.1 to 46.7) in the ATG group and 68.7% (95% CI, 58.4 to 80.7) in the non-ATG group (P<0.001). The rate of 2-year relapse-free survival was similar in the ATG group and the non-ATG group (59.4% [95% CI, 47.8 to 69.2] and 64.6% [95% CI, 50.9 to 75.3], respectively; P=0.21), as was the rate of overall survival (74.1% [95% CI, 62.7 to 82.5] and 77.9% [95% CI, 66.1 to 86.1], respectively; P=0.46). There were no significant between-group differences in the rates of relapse, infectious complications, acute GVHD, or adverse events. The rate of a composite end point of chronic GVHD-free and relapse-free survival at 2 years was significantly higher in the ATG group than in the non-ATG group (36.6% vs. 16.8%, P=0.005). CONCLUSIONS: The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (Funded by the Neovii Biotech and the European Society for Blood and Marrow Transplantation; ClinicalTrials.gov number, NCT00678275.).